Bonus Presentations

June 8

7:10 am

—

7:55 am

Non-CME/CE Presentation

An Established Therapy for Treatment-Resistant Depression (TRD) in Adults

Sponsored by: Acadia Pharmaceuticals

Gustavo Alva, MD, DFAPA

Dr. Alva will discuss educational information about hallucinations and delusions associated with Parkinson’s disease (PD) psychosis, including the symptoms of PD psychosis, a non-motor aspect of PD, and how they progress over time; the impact and burden of PD psychosis on patients, their caregivers, and society; and the relevant treatment considerations when addressing PD psychosis. Dr. Alva will also review clinical efficacy for a treatment option and real-world evidence from retrospective analyses investigating the risk of all-cause mortality among patients with PD psychosis treated with atypical antipsychotics.

June 9

12:10 pm

—

12:55 pm

Non-CME/CE Presentation

Moving Forward: An Informed Approach to the Diagnosis and Treatment of Tardive Dyskinesia

Sponsored by: Karuna Therapeutics

Christoph U. Correll, MD

June 8

9:35 am

—

10:35 am

Independent CME Presentation

Schizophrenia and TAAR1: Exploring New Pathways to Treatment

Supported by an independent educational grant from Sunovion Pharmaceuticals Inc. and Otsuka America Pharmaceutical, Inc.

Additional 1.0 hours of CME credit

Leslie Citrome, MD, MPH; Christoph U. Correll, MD; Jonathan Meyer, MD

This live program features 3 expert faculty who will discuss rapidly evolving receptor science in schizophrenia treatment research and how this evolution may impact future clinical practice. In particular, the content will address novel understandings in the neural pathways involved in the pathophysiology of schizophrenia and the influence of trace-amine associated receptors (TAAR), current limitations in available schizophrenia treatment, and emerging data on treatments targeting TAAR1

June 9

9:30 am

—

10:30 am

Independent CME Presentation

The Great Major Depressive Disorder Case Challenge

Supported by an educational grant from Axsome Therapeutics, Inc.

Additional 1.0 hours of CME credit

Joseph Goldberg, MD; Sagar Parikh, MD; Michael Thase, MD

The Hybrid Symposium will feature a lively and interactive “test and teach” format to engage the audience. The faculty will utilize 2 unique patient case scenarios to review MDD clinical considerations, such as predicting relapse or recurrence, identifying patients who may benefit from a rapid-acting antidepressant, and individualizing treatment selection. The presented case scenarios “test” learners’ knowledge/competence in managing complex cases of MDD. Learners are prompted to determine the appropriate treatment and follow-up for the patient using interactive polling, and the faculty “teach” learners by providing a detailed explanation of the most appropriate response to highlight evidence-based recommendations and innovative treatment strategies.